文献速递银屑病与炎症性皮肤病

Ixekizumab与Guselkumab头对头比较:中重度斑块状银屑病24周疗效与安全性

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
PubMed 文献 · Br J Dermatol · 2020-10-25

IXORA-R随机双盲试验纳入1027例中重度斑块状银屑病患者,比较IL-17A抑制剂Ixekizumab与IL-23p19抑制剂Guselkumab。第24周时Ixekizumab在PASI 100上非劣于Guselkumab(50% vs. 52%),但指甲完全清除率更高(52% vs. 31%),且起效更快、累积获益更大。

要点

  • 第24周PASI 100:Ixekizumab 50% vs. Guselkumab 52%,非劣效,差异无统计学意义。

核心结论

  • Ixekizumab在完全皮肤清除方面非劣于Guselkumab,在指甲清除方面优于Guselkumab。
  • Ixekizumab起效更快,累积获益更大,安全性特征与已知一致。

研究设计与样本

  • 随机、双盲、头对头试验(IXORA-R),纳入1027例中重度斑块状银屑病成人患者。
  • 纳入标准:sPGA≥3、PASI≥12且受累体表面积≥10%。
  • 1027例随机分配,90%完成试验(Ixekizumab组465/520,Guselkumab组459/507)。

关键数值与推荐

  • 严重不良事件频率:两组均为3%。

临床怎么用

  • 对于中重度斑块状银屑病,Ixekizumab和Guselkumab均可实现高比例完全皮肤清除。
  • 需快速起效或关注指甲清除时,Ixekizumab可能更具优势。
  • 两者安全性相当,严重不良事件频率均为3%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at week 12. OBJECTIVES: To compare skin and nail clearance and patient-reported outcomes for ixekizumab vs. guselkumab, up to week 24. METHODS: IXORA-R enrolled adults with moderate-to-severe plaque psoriasis, defined as static Physician's Global Assessment ≥ 3, PASI ≥ 12 and involved body surface area ≥ 10%. Statistical comparisons were performed using the Cochran-Mantel-Haenszel test stratified by pooled site. Time-to-first-event comparisons were performed using Kaplan-Meier analysis, and P-values were generated using adjusted log-rank tests stratified by treatment group. Cumulative days at clinical and patient-reported responses were compared by ancova. The trial was registered with ClinicalTrials.gov (NCT03573323). RESULTS: Of the 1027 patients randomly assigned, 90% completed the trial (465 of 520 ixekizumab and 459 of 507 guselkumab). As early as week 2 and through week 16, more patients on ixekizumab achieved PASI 100 (P < 0·01). At week 24, ixekizumab was noninferior to guselkumab (50% vs. 52%, difference -2·3%), with no statistically significant difference in PASI 100 (P = 0·41). More patients receiving ixekizumab showed completely clear nails at week 24 (52% vs. 31%, P = 0·007). The median time to first PASI 50/75/90 and PASI 100 were 2 and 7·5 weeks shorter, respectively, for patients on ixekizumab vs. guselkumab (P < 0·001). Patients on ixekizumab also had a greater cumulative benefit, with more days at PASI 90 and 100, with Dermatology Life Quality Index of 0 or 1, and itch free (P < 0·05). The frequency of serious adverse events was 3% for each group, with no new safety signals. CONCLUSIONS: Ixekizumab was noninferior to guselkumab in complete skin clearance and superior in clearing nails at week 24. Ixekizumab cleared skin more rapidly in patients with moderate-to-severe plaque psoriasis, with a greater cumulative benefit, than guselkumab. Overall, the safety findings were consistent with the known safety profile for ixekizumab.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2020. PMID: 32880909. doi:10.1111/bjd.19509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。